FOURTH AMENDMENT TO LEASELease Agreement • March 3rd, 2016 • Fate Therapeutics Inc • Biological products, (no disgnostic substances)
This Fourth Amendment (the “Amendment”) to Lease is made as of March 2, 2015, by and between ARE-3535/3565 GENERAL ATOMICS COURT, LLC, a Delaware limited liability company (“Landlord”), and FATE THERAPEUTICS, INC., a Delaware corporation (“Tenant”).
EMPLOYMENT AGREEMENTEmployment Agreement • March 3rd, 2016 • Fate Therapeutics Inc • Biological products, (no disgnostic substances) • California
WHEREAS, this Employment Agreement (the “Agreement”) is entered into on January 12, 2016 and effective as of December 1, 2015 (the “Effective Date”) by and between Fate Therapeutics, Inc. (the “Company”) and J. Scott Wolchko (the “Executive”) in connection with the Executive’s promotion from Chief Financial Officer and Chief Operating Officer to President and Chief Executive Officer of the Company (“CEO”);
THIRD AMENDMENT TO LEASE AGREEMENTLease Agreement • March 3rd, 2016 • Fate Therapeutics Inc • Biological products, (no disgnostic substances)
THIS THIRD AMENDMENT TO LEASE AGREEMENT (this “Third Amendment”) is made as September 2nd, 2014 (“Effective Date”), by and between ARE-3535/3565 GENERAL ATOMICS COURT, LLC, a Delaware limited liability company (“Landlord”), and FATE THERAPEUTICS, INC., a Delaware corporation (“Tenant”).
SUBLEASESublease • March 3rd, 2016 • Fate Therapeutics Inc • Biological products, (no disgnostic substances)
